Revance Therapeutics | RVNC - Interest Expense On Debt


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Revance Therapeutics

Revance Therapeutics reported $4.5M in Interest Expense on Debt for its fiscal quarter ending in March of 2023.


Interest Expense On Debt Change
ALKERMES ALKS:US USD 5.29M 519K
Bristol-Myers Squibb BMY:US USD 288M 6M
Eli Lilly LLY:US USD 102.8M 18.8M
Endo International ENDP:US USD 263K 540K
J&J JNJ:US USD 215M 38M
Neurocrine Biosciences NBIX:US USD 1.1M 0
P&G PG:US USD 222M 51M
Pacira PCRX:US USD 9.59M 1.45M
Revance Therapeutics RVNC:US USD 4.5M 745K
Supernus Pharmaceuticals SUPN:US USD 1.19M 22K